Vericel is leaning on a bigger sales push and a new production site to grow its cartilage repair therapy, while also building out its burn-care business to add a steadier second engine. The upside hinges on doctors keeping up adoption and insurers staying supportive, because any slowdown could quickly hit growth and profits.Read more
Catalysts About Vericel Vericel develops and manufactures advanced cell therapies for sports medicine and burn care, including MACI for cartilage repair and Epicel and NexoBrid in burn care. What are the underlying business or industry changes driving this perspective?Read more
Key Takeaways Expanding surgeon network, label extensions, and rising regenerative therapy demand are fueling market penetration, revenue growth, and long-term diversification opportunities. Operational improvements and strong payer acceptance are supporting margin expansion, increased profitability, and stable long-term financial performance.Read more
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
